3-phenyl-5-methyl-1H-indazole | 57614-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-phenyl-5-methyl-1H-indazole
• 英文别名: 5-Methyl-3-phenylindazole；3-phenyl-5-methylindazole；5-methyl-3-phenyl-1(2)H-indazole；5-Methyl-3-phenyl-1H-indazole
• CAS: 57614-16-1
• 化学式: C₁₄H₁₂N₂
• 分子量: 208.263
• InChiKey: BKFJFOATAKURAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-phenyl-5-methyl-1H-indazole 、 LXM-18 在 氢氧化钾 作用下， 以 甲苯 为溶剂， 生成 1H-Indazole, 5-methyl-3-phenyl-1-[4-(4-phenylpiperazin-1-yl)butyl]-
  参考文献：
  名称：

  Andronati; Sava; Makan, Pharmazie, 1999, vol. 54, # 2, p. 99 - 101

  摘要：

  DOI：
• 作为产物：
  描述：

  (2-氨基-5-甲基苯基)(苯基)甲酮 在 盐酸 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 生成 3-phenyl-5-methyl-1H-indazole
  参考文献：
  名称：

  Andronati; Sava; Makan, Pharmazie, 1999, vol. 54, # 2, p. 99 - 101

  摘要：

  DOI：

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in <i>Candida albicans</i>
  作者：Willmen Youngsaye、Cathy L Hartland、Barbara J Morgan、Amal Ting、Partha P Nag、Benjamin Vincent、Carrie A Mosher、Joshua A Bittker、Sivaraman Dandapani、Michelle Palmer、Luke Whitesell、Susan Lindquist、Stuart L Schreiber、Benito Munoz

  DOI：10.3762/bjoc.9.171

  日期：——

  The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure–activity relationships led to the discovery of ML212.

  国家卫生研究院分子图书馆和探针生产中心网络（NIH-MLPCN）筛选了超过300,000种化合物，以评估它们恢复对耐药念珠菌的氟康唑敏感性的能力。还加入了额外的对照筛选，以去除对哺乳动物或真菌细胞有毒的物质。选择了具有所需生物活性特征的取代吲唑化合物进行进一步开发，并初步研究结构-活性关系导致了ML212的发现。
• Pyrazoloindazole derivatives and bronchodilating composition
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US04409234A1

  公开（公告）日：1983-10-11

  Novel pyrazoloindazole derivatives of the formula ##STR1## wherein R.sub.1 is a hydrogen atom, halogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxyl group or benzyloxyl group; R.sub.2 is a hydrogen atom, a halogen atom, a lower alkyl group or phenyl group (provided R.sub.1 and R.sub.2 are not hydrogen at the same time); and X.sup..crclbar. is a halide ion, a hydroxide ion, a methanesulfonate ion, a p-toluene sulfonate ion, a sulfate ion, a nitrate ion, a carbonate ion, an acetate ion, a benzoate ion or a salicylate ion, a process for preparing the derivatives, and a pharmaceutical composition containing the same are disclosed. The derivatives have good bronchodilating action for human without exhibiting substantially bad effects on the functioning of heart, and therefore, they are useful as a drug.

  公开了一种式为##STR1##的新型吡唑并吲唑衍生物，其中R.sub.1为氢原子，卤素原子，羟基，较低烷基，较低烷氧基或苄氧基；R.sub.2为氢原子，卤素原子，较低烷基或苯基（前提是R.sub.1和R.sub.2不同时为氢原子）；X.sup..crclbar.为卤素离子，羟离子，甲磺酸离子，对甲苯磺酸离子，硫酸离子，硝酸离子，碳酸离子，乙酸离子，苯甲酸离子或水杨酸离子。公开了制备这些衍生物的方法以及含有这些衍生物的制药组合物。这些衍生物在不会对心脏功能产生实质性不良影响的情况下，对人体具有良好的支气管扩张作用，因此它们是有用的药物。